Ranbaxy Pharmaceuticals Inc. : Ranbaxy REMS

	Home \| Careers \| Contact Us \| Sitemap
	Other Country Sites	Search

Home > Ranbaxy REMS

Ranbaxy Approved Risk Evaluation and Mitigation Strategies (REMS)

Keyword

Click

for Approval Letter Click

for Additional Document

Name	Application	REMS Approved	REMS Components	AD
Ciprofloxacin Tablets, USP 250/500/750 mg	ANDA 075747	07/22/2009	Ciprofloxacin Tablets-Medication Guide-FDA_10
Fluoxetine Capsules 40 mg	ANDA 076990	08/30/2010	Fluoxetine Capsules-Med Guide-5080811
Ofloxacin Tablets-200/300/400 mg	ANDA 076220	03/10/2011	Medication Guide Feb-2011

Page: 1 of 1

For any help related to accessing/downloading/printing of the desired document, please click here for technical assistance. This link shall not be used for reporting any Adverse Drug Events (ADEs).

You are encouraged to report all ADEs related to prescription drugs to the FDA: www.fda.gov/medwatch or call 1-800-FDA-1088.

For product information, call 1-800-406-7984.